Nombre del producto:3-Chloro-5-(p-tolyl)-1,2,4-triazine

IUPAC Name:3-chloro-5-(4-methylphenyl)-1,2,4-triazine

CAS:1368414-41-8
Fórmula molecular:C10H8ClN3
Pureza:95%
Número de catálogo:CM121753
Peso molecular:205.65

Unidad de embalaje Stock disponible Precio($) Cantidad
CM121753-100mg in stock ƱƻƱ
CM121753-250mg in stock ƱȌDz
CM121753-1g in stock ȦȦɐ

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :1368414-41-8
Fórmula molecular:C10H8ClN3
Punto de fusión:-
Código de sonrisas:CC1=CC=C(C2=CN=NC(Cl)=N2)C=C1
Densidad:
Número de catálogo:CM121753
Peso molecular:205.65
Punto de ebullición:
Nº Mdl:MFCD21962268
Almacenamiento:

Category Infos

Triazines
Triazines are an important class of six-membered aromatic heterocycles with three nitrogen atoms that give rise to three regioisomers: 1,2,4-triazines, 1,2,3-triazines, and 1,3, 5-triazine. 1,2,3-Triazines show remarkable reactivity and have attracted attention for their medicinal value. Triazine compounds fused with other carbon and heterocycles are stable and have a broad spectrum of pharmacological activities.

Column Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Lorundrostat
Mineralys Therapeutics announced that the first subject has been dosed in the Launch-HTN pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment. Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products